1. Scrip
  2. >>COVID-19

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: AstraZeneca’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer partners up for respiratory therapy.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 May 2024, including: AstraZeneca PLC’s Vaxzevria farewell; the next wave of cardiometabolics; Pfizer Inc. recruits prominent analyst: foundation pleas for China rare disease therapies; and Gossamer Bio, Inc. partners up for respiratory therapy.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up" - Scrip, 8 May, 2024.)

(Also see "Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies" - Scrip, 8 May, 2024.)

(Also see "Pfizer Recruits Industry Analyst Baum To Advance Corporate Strategy" - Scrip, 6 May, 2024.)

(Also see "China’s First Non-Profit Rare Disease Foundation Pleas For Therapies" - Scrip, 8 May, 2024.)

(Also see "Gossamer Partners With Chiesi To Accelerate Seralutinib Development" - Scrip, 6 May, 2024.)

Citeline · Scrip's Five Must-Know Things - 13 May 2024

Open Media

More from COVID-19

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

 
• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

 
• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.

More from Scrip

Will They Or Won’t They? Tariff Question Looms For Drugmakers

 
• By Jessica Merrill

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By Joseph Haas

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By Kevin Grogan

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.